curve imageHomeProductsContact UsSearch
CorporateAbout PallInvestor InformationPress ReleasesEventsWorldwide Locations
Main Image Public Relations Contact Information

You are about to review presentations, news releases, reports and/or filings of Pall Corporation that contain time-sensitive information. The information contained therein is only accurate as of the date thereof. Pall Corporation will not be reviewing or updating the material that is contained in these items after the date thereof. The information contained therein may be updated, amended, supplemented or otherwise altered by subsequent presentations, news releases, reports and/or filings by Pall Corporation.
Printer-Friendly variant for news releases
Pall Corporation Sales Up 18.3% in Third Quarter



Back

Pall Corporation Sales Up 18.3% in Third Quarter

East Hills, NY (May 28, 2008) - - Pall Corporation (NYSE: PLL) today reported strong sales for its third quarter which ended April 30, 2008. Full results will be released on June 9 after the market closes.

Sales Overview

Sales for the quarter were $661.7 million, an increase of 18.3% compared with the third quarter last year. Sales for the nine months ended April 30, 2008 were approximately $1.8 billion, up 15.3% compared with the nine months ended April 30, 2007.

In local currency (LC), sales increased $53.5 million, or 9.6%, in the quarter and $132.2 million, or 8.3%, for the nine months.

Eric Krasnoff, Chairman and CEO, stated, Sales growth was broad-based across markets and geographies. Over two-thirds of our revenue is now generated outside the U.S. System sales were particularly strong with an increase of 66% and represent 12% of total sales in the quarter. Palls Total Fluid ManagementSM capability is clearly resonating with customers."

Life Sciences - Third Quarter Sales Highlights

(Dollar Amounts in Thousands)      
 

Sales:

APR. 30, 2008

% CHANGE

% CHANGE IN LC

Medical $ 124,555 2.1 (2.9)
BioPharmaceuticals   128,441 19.9 9.9
Total Life Sciences segment $ 252,996 10.5 3.1

Within Life Sciences, sales in BioPharmaceuticals increased almost 10% with growth in consumables exceeding 6%. Consumable sales were particularly strong in Europe. This was aided by increased production of vaccines and the expansion of biotech capacity in Europe. Biotech investment continues to be strong in the U.S. and is beginning to ramp up in Europe and Asia.

As expected, Medical sales decreased just under 3% on lower Blood Filtration sales. Sales of other products within the Medical portfolio, including hospital water filters and disposable systems for cell therapy applications, posted solid results. Sales of laboratory products increased near double-digits.

Industrial - Third Quarter Sales Highlights

(Dollar Amounts in Thousands)      
 

Sales:

APR. 30, 2008

% CHANGE

% CHANGE IN LC

General Industrial $ 252,253 30.5 19.1
Aerospace and Transportation 79,143 26.8 20.1
Microelectronics   77,288 3.5 (4.0)
Total Industrial segment $ 408,684 23.7 14.1

Pall Industrial delivered a very strong quarter. Every market within General Industrial reported double-digit sales increases. Growth in Municipal Water and Food and Beverage was particularly robust. Systems sales, which are concentrated within General Industrial, grew close to 60%. The installed base of systems within these markets helped to drive consumable sales growth of nearly 10%. The combination of strong system and consumable sales is the goal of Pall's Total Fluid Management strategy.

Within Aerospace and Transportation, Commercial Aerospace sales grew 16% driven by strong after-market demand and increased sales to airframe manufacturers. Military sales increased about 31% driven by helicopter upgrade projects in the U.S. and military water systems in Asia.

Microelectronics sales were down 4% as the cyclical downturn in the semiconductor market continues. Our macroelectronics market continued to grow along with demand for high-tech consumer electronics.

Conclusion

Mr. Krasnoff concluded, We are pleased with our sales progress and look forward to issuing full third quarter results.

Third Quarter Earnings Release and Conference Call

The Company will report full third quarter fiscal year 2008 earnings results on Monday, June 9, 2008, after the market closes.

A conference call to review the Company's results, market trends and future outlook will be broadcast live over the Internet at 8:30 am ET on Tuesday, June 10, 2008. Eric Krasnoff, Chairman and CEO; and Lisa McDermott, CFO, will host the call.

The call will be webcast and individuals can access it at www.pall.com/investor. Listening to the webcast requires audio speakers and Microsoft Windows Media Player software. The webcast will be archived for 30 days. The webcast will be archived for 30 days. Investors can also subscribe to the RSS feed to be notified of Pall's upcoming investor event schedule at www.pall.com/rss.

About Pall Corporation

Pall Corporation is the global leader in the rapidly growing field of filtration, separation and purification. Pall is organized into two businesses: Life Sciences and Industrial. These businesses provide leading-edge products to meet the demanding needs of customers in biotechnology, pharmaceutical, transfusion medicine, energy, electronics, water purification, aerospace, transportation and broad industrial markets. Total revenues for fiscal year 2007 were $2.2 billion. The Company is headquartered in East Hills, New York and has extensive operations around the world. For more information visit Pall at http://www.pall.com/.

Forward-Looking Statements

The matters discussed in this release contain forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this release and in the Companys other written and oral reports are based on current Company expectations and are subject to risks and uncertainties, which could cause actual results to differ materially. All statements regarding future performance, earnings projections, earnings guidance, managements expectations about its future cash needs and effective tax rate, and other future events or developments are forward-looking statements. Such risks and uncertainties include, but are not limited to: risks relating to the Companys restatement of prior period financial statements, including the risks associated with the pending IRS audit and pending SEC and Department of Justice investigations and litigation proceedings; risks associated with the Companys planned cash management initiatives, which may result in changes in the Company's effective tax rate; changes in product mix and product pricing may affect the Companys operating results particularly as the systems business expands in which significantly longer sales cycles are experienced with less predictable revenue and profitability and less certainty of future revenue streams from related consumable product offerings and services; increases in costs of manufacturing and operating costs, including energy and raw materials; the Companys ability to achieve the savings anticipated from its cost reduction and margin improvement initiatives including the timing of completion of its facilities rationalization initiative; fluctuations in foreign currency exchange rates and interest rates; regulatory approval or market acceptance of new technologies; changes in demand for the Companys products and business relationships with key customers and suppliers including delays or cancellations in shipments; success in enforcing patents and protecting proprietary products and manufacturing techniques; risks associated with the completion or integration of acquisitions; domestic and international competition; and global and regional economic conditions, including particularly the impact of current challenging conditions in the United States that may also have global implications; and legislative, regulatory and political developments. The Company makes these statements as of the date of this disclosure and undertakes no obligation to update them. You should carefully consider these factors as well as the additional risk factors outlined in more detail in our most recent Annual Report on Form 10-K under Item 1A, Risk Factors, and in other filings the Company makes with the Securities and Exchange Commission.

Management uses certain non-GAAP measurements to assess the Company's current and future financial performance. The non-GAAP measurements do not replace the presentation of Pall's GAAP financial results. These measurements provide supplemental information to assist management in analyzing the Company's financial position and results of operations. The Company has chosen to provide this information to facilitate meaningful comparisons of past, present and future operating results and as a means to emphasize the results of ongoing operations.

PALL CORPORATION
SUPPLEMENTAL SEGMENT SALES INFORMATION BY MARKET AND GEOGRAPHY
(Unaudited)
(Dollar Amounts in Thousands)
       

 

THIRD QUARTER ENDED APR. 30, 2008 APR. 30, 2007 % CHANGE

EXCHANGE
RATE
IMPACT

% CHANGE
IN LOCAL
CURRENCY

 

Life Sciences

-------- Increase/(Decrease) --------

By Market:
Medical $ 124,555 $ 121,934 2.1 $ 6,182 (2.9)  
BioPharmaceuticals   128,441   107,110 19.9   10,715 9.9
Total Life Sciences $ 252,996 $ 229,044 10.5 $ 16,897 3.1
 
By Geography:
Western Hemisphere $ 95,387 $ 97,419 (2.1)   $ 439 (2.5)
Europe 125,068 102,934 21.5 13,240 8.6
Asia   32,541   28,691 13.4   3,218 2.2
Total Life Sciences $ 252,996 $ 229,044 10.5 $ 16,897 3.1
 
 

Industrial

By Market:
General Industrial $ 252,253 $ 193,231 30.5 $ 22,102 19.1
Aerospace and Transportation 79,143 62,417 26.8 4,202 20.1
Microelectronics   77,288   74,655 3.5   5,619 (4.0)  
Total Industrial $ 408,684 $ 330,303 23.7 $ 31,923 14.1
 
By Geography:
Western Hemisphere $ 108,621 $ 93,811 15.8 $ 876 14.9
Europe 170,688 128,279 33.1 19,261 18.1
Asia   129,375   108,213 19.6   11,786 8.7
Total Industrial $ 408,684 $ 330,303 23.7 $ 31,923 14.1

 

PALL CORPORATION

SUPPLEMENTAL SEGMENT SALES INFORMATION BY MARKET AND GEOGRAPHY
(Unaudited)
(Dollar Amounts in Thousands)
       

 

NINE MONTHS ENDED APR. 30, 2008 APR. 30, 2007 % CHANGE

EXCHANGE
RATE
IMPACT

% CHANGE
IN LOCAL
CURRENCY

 

Life Sciences

--------- Increase/(Decrease) ---------
By Market:
Medical $ 360,004 $ 345,051 4.3 $ 14,877 0.0
BioPharmaceuticals 352,086 288,930 21.9 24,890 13.2
Total Life Sciences $ 712,090 $ 633,981 12.3 $ 39,767 6.0
 
By Geography:
Western Hemisphere $ 278,286 $ 271,056 2.7 $ 1,197 2.2
Europe 343,561 282,855 21.5 31,866 10.2
Asia 90,243 80,070 12.7 6,704 4.3
Total Life Sciences $ 712,090 $ 633,981 12.3 $ 39,767 6.0
 
 

Industrial

By Market:
General Industrial $ 692,947 $ 565,279 22.6 $ 51,295 13.5
Aerospace and Transportation 216,415 183,484 17.9 10,398 12.3
Microelectronics 226,982 220,821 2.8 11,181 (2.3)
Total Industrial $ 1,136,344 $ 969,584 17.2 $ 72,874 9.7
 
By Geography:
Western Hemisphere $ 304,530 $ 279,726 8.9 $ 2,622 7.9
Europe 452,456 379,399 19.3 44,943 7.4
Asia 379,358 310,459 22.2 25,309 14.0
Total Industrial $ 1,136,344 $ 969,584 17.2 $ 72,874 9.7

###


Contact:
Pall Corporation
Patricia Iannucci
V.P. Investor Relations & Corporate Communications
Telephone: 516-801-9848
Email: piannucci@pall.com

Back